Clinical Trial

Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old

Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is an open-label nonrandomized exploratory proof of concept and descriptive 4-year immunogenicity study to assess immunogenicity after administration of a 2-dose regimen of 9-valent human papillomavirus vaccine (9vHPV) vaccine separated by 12 months (months 0, 12).
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-04-12; most recent amendment 2026-06-29.
Status change: Recruiting → Active, Not Recruiting 2024-10-03
Status change: Not Yet Recruiting → Recruiting 2022-10-01
Trial Details
NCT Number NCT05329961
Lead Sponsor Boston Medical Center
Collaborators: Merck Sharp & Dohme LLC
Conditions Human Papilloma Virus
Enrollment 155 participants
Start Date 2022-09-26
Primary Completion 2028-07 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-01